Evidence map›Paper›PMID 41184776›Full record

ArticleMolecular medicine (Cambridge, Mass.)2025

Nociceptor α7nAChR activation blunts neuronal HMGB1 release and attenuates inflammation and nociceptive behavior.

Huan Yang, Timothy S Morgan, Serena Petruzzelli, Okito Hashimoto, Tyler D Hepler, Aisling Tynan, Saher Chaudhry, Michael Brines, Ulf Andersson, Sangeeta S Chavan and 1 more

Abstract read
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Huan YangInstitute for Bioelectronic Medicine, Feinstein Institutes for Medical Research, 350 Community Drive, Manhasset, NY, 11030, United States. hyang@northwell.edu.
Timothy S MorganInstitute for Bioelectronic Medicine, Feinstein Institutes for Medical Research, 350 Community Drive, Manhasset, NY, 11030, United States.
Serena PetruzzelliInstitute for Bioelectronic Medicine, Feinstein Institutes for Medical Research, 350 Community Drive, Manhasset, NY, 11030, United States.
Okito HashimotoInstitute for Bioelectronic Medicine, Feinstein Institutes for Medical Research, 350 Community Drive, Manhasset, NY, 11030, United States.
Tyler D HeplerInstitute for Bioelectronic Medicine, Feinstein Institutes for Medical Research, 350 Community Drive, Manhasset, NY, 11030, United States.
Aisling TynanInstitute for Bioelectronic Medicine, Feinstein Institutes for Medical Research, 350 Community Drive, Manhasset, NY, 11030, United States.
Saher ChaudhryInstitute for Bioelectronic Medicine, Feinstein Institutes for Medical Research, 350 Community Drive, Manhasset, NY, 11030, United States.
Michael BrinesInstitute for Bioelectronic Medicine, Feinstein Institutes for Medical Research, 350 Community Drive, Manhasset, NY, 11030, United States.
Ulf AnderssonDepartment of Women's and Children's Health, Karolinska Institute, Karolinska University Hospital, Stockholm, 17176, Sweden.
Sangeeta S ChavanInstitute for Bioelectronic Medicine, Feinstein Institutes for Medical Research, 350 Community Drive, Manhasset, NY, 11030, United States.
Kevin J TraceyInstitute for Bioelectronic Medicine, Feinstein Institutes for Medical Research, 350 Community Drive, Manhasset, NY, 11030, United States. kjtracey@northwell.edu.

Funding

Molecular Basis of Bioelectronic MedicineR35GM118182 · NIGMS · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI TRACEY, KEVIN J · 2016 to 2025
$7.3M
National Institute of Health (NIH): National Institute of General Medical Services (NIGMS) R35GM118182
6 · The paper itself

Abstract

backgroundHigh Mobility Group Box 1 (HMGB1) is a nuclear protein that upon extracellular release acts as an alarmin to initiate and amplify inflammation. HMGB1 release from nociceptors contributes to both inflammation and pain; however, the mechanisms for its regulation remain incompletely understood. The cholinergic anti-inflammatory pathway, mediated by α7 nicotinic acetylcholine receptor (α7nAChR) activation, inhibits HMGB1 release from immune cells and reduces inflammation. This study investigates whether α7nAChR signaling similarly inhibits HMGB1 release from nociceptors, thereby affecting pain and inflammation.

methodsDorsal root ganglia (DRG) neurons were isolated from C57BL/6 or VGlut2-Cre/ChR2-YFP mice (expressing ChR2 in sensory neurons for optogenetic stimulation at 470 nm). HMGB1 release in vitro was triggered by optogenetic stimulation or exposure to capsaicin (5 µM), in the presence or absence of cholinergic agonists (acetylcholine, GTS-21, PNU-282987), and subsequently measured by ELISA. Immunohistochemistry was used to visualize cellular HMGB1 localization. In vivo models, including optogenetic stimulation and formalin-induced pain-like behavior, were used to evaluate the effects of cholinergic agonists on pain-like behavior, mechanical allodynia and inflammation. α7nAChR knockout (KO) mice served to determine receptor-specific effects. Levels of proinflammatory mediators calcitonin gene-related peptide (CGRP), substance P, HMGB1, and IL-6 were also measured.

resultsOptogenetic stimulation of cultured DRG neurons significantly increased HMGB1 release, which was markedly inhibited by cholinergic agonists. Similarly, capsaicin-induced HMGB1 release was suppressed by acetylcholine, GTS-21, and PNU-282987, promoting HMGB1 retention within the nucleus; this effect was abolished in α7nAChR KO neurons. In contrast, the release of CGRP and substance P following optogenetic or capsaicin stimulation of DRG neurons from wild-type mice was not influenced by cholinergic agonists. In vivo, GTS-21 reduced pain-like behaviors and mechanical allodynia in both the formalin-induced and optogenetically-stimulated nociceptive behavior models, as demonstrated by reduced mechanical allodynia and extracellular HMGB1 levels. These effects were absent in α7nAChR KO mice, confirming the critical role of α7nAChR in mediating these responses.

conclusionThis study reveals a novel α7nAChR-dependent cholinergic mechanism that reduces nociceptive behavior and inflammation by retaining nuclear HMGB1 in nociceptors. Cholinergic agonists may serve as promising therapeutic agents to mitigate nociceptive behavior and inflammation by targeting α7nAChR in sensory neurons.

Indexed as

alpha7 Nicotinic Acetylcholine ReceptorHMGB1 ProteinInflammationNeuronsNociceptionNociceptorsAnimalsGanglia, SpinalMaleMiceMice, Inbred C57BLOptogeneticsPainalpha7 Nicotinic Acetylcholine ReceptorHMGB1 ProteinHMGB1 protein, mouseCholinergic agonistsCholinergic anti-inflammatory pathwayDorsal root gangliaHMGB1InflammationPain-like behaviorα7 nicotinic acetylcholine receptor

Identifiers

PMID41184776
PMCPMC12581301

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.